The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma.

Jiao LiHui YuXing WangYingying YeWei FangNing DingLan MiLingyan PingXiaogan WangYuqin SongJun Zhu

Published in: Cancer control : journal of the Moffitt Cancer Center (2022)

SGK1 may be a novel candidate therapeutic target and simultaneous inhibition of SGK1 and BTK may be a promising therapeutic strategy for MCL patients. Further pre-clinical and even clinical studies of SGK1 inhibitor or combination with BTK inhibitor are essential.

Keyphrases

tyrosine kinase
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
protein kinase
patient reported